Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 1797753)

Published in Antimicrob Agents Chemother on December 04, 2006

Authors

Ying Ying Chan1, Yong Mei Ong, Kim Lee Chua

Author Affiliations

1: Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore.

Articles cited by this

Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23

Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob Agents Chemother (1999) 4.29

Antibiotic entry into human polymorphonuclear leukocytes. Antimicrob Agents Chemother (1982) 3.62

Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria. Semin Cell Dev Biol (2001) 2.47

Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 1.96

Flagella are virulence determinants of Burkholderia pseudomallei. Infect Immun (2003) 1.83

Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis (1989) 1.64

BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei. Antimicrob Agents Chemother (2004) 1.58

Evidence for the existence of a multidrug efflux transporter distinct from NorA in Staphylococcus aureus. Antimicrob Agents Chemother (2000) 1.37

The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J Bacteriol (2005) 1.35

Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol (1989) 1.31

Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob Agents Chemother (1999) 1.31

Recent advances in the treatment of severe melioidosis. Acta Trop (2000) 1.28

Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents (2001) 1.26

Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob Agents Chemother (2003) 1.21

The potential management of resistant infections with non-antibiotics. J Antimicrob Chemother (1997) 1.21

Enhanced binding of polycationic antibiotics to lipopolysaccharide from an aminoglycoside-supersusceptible, tolA mutant strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1988) 1.17

Pseudomonas pseudomallei liver abscesses: a clinical, laboratory, and ultrasonographic study. Clin Infect Dis (1992) 1.14

Bichat guidelines for the clinical management of glanders and melioidosis and bioterrorism-related glanders and melioidosis. Euro Surveill (2004) 0.98

Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes. Biochim Biophys Acta (1983) 0.95

Thioridazine reduces resistance of methicillin-resistant staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In Vivo (2006) 0.88

Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J Infect Chemother (2002) 0.86

Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem Pharmacol (1990) 0.85

Enhancement of Burkholderia cepacia antimicrobial susceptibility by cationic compounds. J Antimicrob Chemother (1997) 0.84

Acute suppurative parotitis. J Med Assoc Thai (2004) 0.77

Tuning of the selectivity in capillary electrophoresis by cyclodextrins illustrated by the separation of some structurally related phenothiazines. J Capillary Electrophor (1999) 0.76

Articles by these authors

Model of differential susceptibility to mucosal Burkholderia pseudomallei infection. Infect Immun (2002) 1.99

Characterization of Burkholderia pseudomallei infection and identification of novel virulence factors using a Caenorhabditis elegans host system. Mol Microbiol (2002) 1.58

The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence. J Bacteriol (2005) 1.35

Control of quorum sensing by a Burkholderia pseudomallei multidrug efflux pump. J Bacteriol (2007) 1.06

CdpA is a Burkholderia pseudomallei cyclic di-GMP phosphodiesterase involved in autoaggregation, flagellum synthesis, motility, biofilm formation, cell invasion, and cytotoxicity. Infect Immun (2010) 1.04

A method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii. BMC Microbiol (2013) 0.93

A role of Burkholderia pseudomallei flagella as a virulent factor. Trans R Soc Trop Med Hyg (2008) 0.92

N-Octanoylhomoserine lactone signalling mediated by the BpsI-BpsR quorum sensing system plays a major role in biofilm formation of Burkholderia pseudomallei. Microbiology (2011) 0.91

Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments. Antimicrob Agents Chemother (2005) 0.90

Disruption of biofilm formation by the human pathogen Acinetobacter baumannii using engineered quorum-quenching lactonases. Antimicrob Agents Chemother (2013) 0.85

Growth-related changes in intracellular spermidine and its effect on efflux pump expression and quorum sensing in Burkholderia pseudomallei. Microbiology (2009) 0.84

A multigene family of Heteractis magnificalysins (HMgs). Toxicon (2008) 0.84

Assessment of the effect of efflux pump inhibitors on in vitro antimicrobial susceptibility of multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents (2013) 0.82

Cloning and molecular characterization of the first aquatic hyaluronidase, SFHYA1, from the venom of stonefish (Synanceja horrida). Gene (2004) 0.79

Synthesis of cyclic di-nucleotidic acids as potential inhibitors targeting diguanylate cyclase. Bioorg Med Chem (2010) 0.76